Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Kristin Blom¹, Jenny Rubin¹, Malin Berglund¹, Malin Jarvius¹, Lena Lenhammar¹, Vendela Parrow¹, Claes Andersson¹, Angelica Loskog², Mårten Fryknäs¹, Peter Nygren² and Rolf Larsson¹*

Abstract

Objective: We recently showed that the anti-helminthic compound mebendazole (MBZ) has immunomodulating activity by inducing a M2 to M1 phenotype switch in monocyte/macrophage models. In the present study we investigated the potential role of protein kinases in mediating this effect.

Results: MBZ potently binds and inhibits Dual specificity tyrosine-phosphorylation-regulated kinase 1B (DYRK1B) with a Kd and an IC50 of 7 and 360 nM, respectively. The specific DYRK1B inhibitor AZ191 did not mimic the cytokine release profile of MBZ in untreated THP-1 monocytes. However, in THP-1 cells differentiated into macrophages, AZ191 strongly induced a pro-inflammatory cytokine release pattern similar to MBZ and LPS/IFNγ. Furthermore, like MBZ, AZ191 increased the expression of the M1 marker CD80 and decreased the M2 marker CD163 in THP-1 macrophages. In this model, AZ191 also increased phospho-ERK activity although to a lesser extent compared to MBZ. Taken together, the results demonstrate that DYRK1B inhibition could, at least partly, recapitulate immune responses induced by MBZ. Hence, DYRK1B inhibition induced by MBZ may be part of the mechanism of action to switch M2 to M1 macrophages.

Keywords: Monocytes and macrophages, Mebendazole, M1 polarisation, DYRK1B

Introduction

Mebendazole (MBZ), a drug commonly prescribed for various forms of helminthic diseases has demonstrated anticancer activity in several in vitro and in vivo model systems [1–11]. In the clinical setting MBZ has also induced tumour responses in therapy-resistant patients with adrenocortical and colorectal cancer [12, 13]. The primary anticancer mechanism of MBZ has been attributed to its ability to target and inhibit tubulin polymerization in tumour cells [3, 4]. However, other mechanisms, such as angiogenesis inhibition [6, 9], apoptosis induction [2, 8] and inhibition of the Hedgehog signalling pathway [14] have been proposed. Moreover, MBZ has also been shown to potently bind to several protein kinases involved in oncogenic signaling [7]. Recently, we showed that MBZ induce a pro-inflammatory tumour-suppressive M1 phenotype in THP-1 monocytes and macrophages which could potentially explain tumour cell killing [15]. We also recently demonstrated that MBZ potentiate the anti-cancer activity of CD3/IL2 activated peripheral blood mononuclear cells (PBMCs) and that this effect was attenuated by removal of CD14+ myeloid cells [16]. Hence, MBZ is seemingly an interesting small molecule drug to tilt the M2 rich tumour microenvironment in favour of M1 macrophage differentiation, which in turn may induce anti-tumour immunity.

In the present study, we investigated the possible role of protein kinases for the immune modulating properties of MBZ in THP-1 monocytes and macrophages. The results show that DYRK1B inhibition could, at least partly, mimic the immune responses induced by MBZ.

*Correspondence: rolf.larsson@medsci.uu.se

¹ Department of Medical Sciences, Division of Cancer Pharmacology and Computational Medicine, Uppsala University, 75185 Uppsala, Sweden

Full list of author information is available at the end of the article

© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
and could be part of the mechanism of action for its macrophage M1 polarisation.

**Main text**

**Methods**

**Materials**

MBZ, AZ191, lipopolysaccharide (LPS), interferon gamma (IFNγ), interleukin-13 (IL13), phorbol-12-myristate-13-acetate (PMA) and interleukin-4 (IL4) were purchased from Sigma Aldrich (Sigma, St. Louis, MO, USA). The compounds were stored as 10 mM stock solutions in dimethylsulfoxide (DMSO, Honeywell, Morris Plains, NJ, USA) or sterile water and further diluted with culture medium (see below).

**Cell culture**

Cell culture was performed as previously described [15]. Monocytoid THP-1 cells were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA) and were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, l-glutamine (2 mM), penicillin/streptomycin (100 U/100 µg/mL) and 0.05 mM 2-mercaptoethanol (Sigma). The cell line was cultured at 37 °C in a humidified atmosphere with 5% CO₂. For the differentiation and polarisation of THP-1 cells to macrophages, PMA (97.2 nM), IFNγ (20 ng/mL), LPS (100 ng/mL), IL4 (20 ng/mL) and 20 ng/mL IL13 (final concentrations) were used according to an established protocol with minor modifications [17]. PMA was added to THP-1 cells seeded into wells of a 12-well plate (Corning). After 30 h incubation, LPS/IFNγ (M1), IL4/IL13 (M2), DMSO (control), AZ191 and MBZ were added to separate wells. After an additional 18 h incubation time the medium was collected and analysed. In some experiments cells were lysed and analysed for phosphoprotein activity.

**Protein kinase assays**

The binding affinities of MBZ were tested in a binding assay (DiscoverX, CA) against DYRK1B kinase tagged with DNA. Compounds that bind the kinase active site and directly or indirectly prevent kinase binding to an immobilised ligand, will reduce the amount of kinase captured on solid support. Conversely, test molecules that do not bind the kinase have no effect on the amount of kinase captured on the solid support. Binding constants were determined with this method using 11-point threefold serial dilutions of the compound. Curves were fitted using a non-linear least square t with the Levenberg–Marquardt algorithm [18]. Inhibition of DYRK1B activity was performed by Reaction labs, USA. Briefly, compounds were tested in 10-dose IC₅₀ mode with threefold serial dilution starting at 10 µM and reactions were carried out at 10 µM ATP. Data are presented as % enzyme activity (relative to DMSO controls).

**Measurement of M1 and M2 surface marker expression**

Surface markers was measured as previously described [15]. THP-1 cells were incubated for 24 h with PMA, DMSO and AZ191. The cells were subsequently washed with cell culture media and incubated for an additional 24 h. Cells were then detached and mixed with the conjugated antibodies CD80-PC7 and CD163-PE (Beckman Coulter, Indianapolis, IN, USA). After 15 min, cells were washed with PBS (Sigma) and subsequently analysed on a Navios flow cytometer (Beckman Coulter) using the Kaluza software (Beckman Coulter).

**Measurement of cytokines and phosphoproteins**

Cytokines and phosphoproteins were measured using the Luminex/MAGPIX system and commercially available kits (Biorad, Hercules, CA) and were performed as described previously [15] and according to the instructions from the manufacturer. Briefly, for the cytokine assay supernatant samples were incubated with beads, detection antibody and streptavidin-PE. The fluorescence was subsequently measured using the MAGPIX instrument. For the phosphoprotein assay cell lysates were used and protein concentrations were determined using a Micro-BCA method (ThermoFischer Scientific, Waltham, MA, USA) to obtain equal amounts of samples in the assay.

**Statistical analysis**

Statistical analysis was performed using the Students t-test module in GraphPadPrism (GraphPad Software, San Diego, CA).

**Results and discussion**

We previously showed that MBZ selectively and potently binds to several protein kinases [7]. When repeating and extending the initial kinase screen we noted that MBZ affected the dual specificity tyrosine phosphorylation-regulated kinase 1B (DYRK1B). In concentration–response experiment for binding affinity to DYRK1B, MBZ showed a kD of 7 nM and potently inhibited the kinase activity, with an IC₅₀ of 360 nM (Fig. 1a, b). This should be compared with binding data (kD) for other hit kinases from the screening of the Scanedge and Kinoscan 456 from DiscoverX (Fig. 1c). The Kd of 7 nM for DYRK1B clearly stands out being considerably lower than for other kinases including ABL, BRAF and DYRK1A (Fig. 1c). The 7 nM Kd for MBZ binding to DYRK1B is a low concentration, compared with MBZ inhibition of tubulin polymerisation, which requires concentrations exceeding 1 µM [15]. These results are in accordance
with validated results from the RepurposeVS, a drug repurposing computational platform [19]. DYRK1B is a serine/threonine kinase that is widely expressed in various cells especially in nondividing cells such as myoblasts that exit the cell cycle to terminally differentiate. DYRK1B controls the cellular change from a noncycling G0 state to S phase and also diminish oxidative stress by reducing intracellular levels of reactive oxygen species (ROS) [20]. Furthermore, DYRK1B is overexpressed in a subset of cancers and maintains cellular quiescence which increases cell survival in e.g. ovarian-, pancreatic-, and colon cancer [21–23].

Next we tested the effect of MBZ and the selective inhibitor of DYRK1B, AZ191 [24], on cytokine release from THP-1 monocytes. AZ191 did not mimic the cytokine release profile induced by MBZ in untreated THP-1 monocytes (Fig. 2a, b) and only a small effect on IL1β secretion was noted when the cells were primed with LPS (Additional file 1: Fig. S1). In contrast, MBZ at 10 µM strongly induced cytokine release in these cells and in lower concentrations (1 µM) the effect on IL1β secretion could be clearly potentiated by priming with LPS (Fig. 2a and Additional file 1: Fig. S1).

In contrast, in THP-1 cells differentiated to macrophages by PMA, AZ191 induced a M1-like pro-inflammatory cytokine release pattern similar to MBZ and LPS/IFNγ (Fig. 2c–f). MBZ (Fig. 2e), LPS/IFNγ (Fig. 2c) and AZ191 (Fig. 2f) clearly increased both IL1β and TNF (tumour necrosis factor) and decreased VEGF (vascular endothelial growth factor) opposite to the effect of M2 inducing IL13/IL4 stimulation (Fig. 2d). In repeat experiments with IL1β and TNF the effect of AZ191 was statistically significant compared to DMSO control (P < 0.01, n = 4, paired Students t-test). Moreover, AZ191 increased the expression of the M1 marker CD80 and decreased the M2 marker CD163 in the THP-1 macrophage model (Fig. 3a with the original flow cytometry histograms shown in Additional file 2: Fig. S2), corroborating previously published results for MBZ [15].

The difference between THP-macrophages and THP-1 monocytes in response to AZ191 and MBZ is presently unexplained. Monocytoid THP-1 cells are often used as surrogate model for dendritic cells (DCs) in evaluation of allergen potential of small molecules [25–27]. MBZ-induced cytokine release in naive THP-1 cells is dominated by IL1β and IL8, a response considered to reflect maturation of immature DCs to active functional antigen-presenting DCs [25, 28]. Based on the expression profile for 13 gene markers...
for DC activation, the monocytic THP-1 cells significantly more closely resembled the human DC model compared to THP-1 differentiated macrophages [25]. On the other hand, THP-1 macrophages have been reported to closely mimic the phenotype of human macrophages [29]. Thus, these cellular models reflecting DCS and macrophages are different and this may also apply to signaling pathways.

One consequence of DYRK1B inhibition is ERK (extracellular signal-regulated kinase) activation and it has previously been shown that MBZ strongly induces ERK activation [30]. Indeed, although less pronounced than for MBZ, AZ191 dose-dependently increased phospho-ERK activity in THP-1 macrophages (Fig. 3b).

Previous studies have demonstrated that IL1β release require two signals. The first is provided by toll-like-receptor-mediated NF-kappaB activation whereas the second can be mediated by danger signals such as stimulation of ATP receptors or other stimuli including elevated ROS production or perturbation of lysosome integrity [15]. In this study it was demonstrated that high dose MBZ (> 3 µM) activated both signals, the first via TLR8 stimulation, whereas low concentrations (1 µM) only could activate the second one [15]. From the data presented here one can speculate that ERK activation induced by MBZ and AZ191 might be the second signal in PMA differentiated THP-1 macrophages. However, it should be noted that the present results only based on one cell line model only and the relevance to the human immune system remains to be established.

Monocytes and macrophages may express at least two different phenotypes which can be either pro-inflammatory (M1) or anti-inflammatory (M2) [17, 31, 32]. The M1 monocytes/macrophages is characterised by tumor-suppressive properties such as production of cytokines that activate T-cells and can also induce direct cytotoxic anti-tumour effects. The M2 counterpart is the typical phenotype present in solid tumours and exert tumour-supporting functions such as immunosuppression and stimulation of angiogenesis [17, 31, 32]. Small molecules that have the capability to shift the polarisation from M2 to M1 would thus be potentially interesting for cancer therapy. This type of drugs could also be fruitfully combined with other immunotherapy, such as checkpoint inhibitors or CAR T cells. If MBZ is such a drug will require further investigation.

**Limitations**

The work is restricted only to cell line models.

**Additional files**

**Additional file 1: Fig. S1.** The effect of AZ191 and MBZ with and without LPS on IL-1 release in THP-1 monocytes is shown.

**Additional file 2: Fig. S2.** Original flow cytometry histograms from Fig. 3 is shown.

**Abbreviations**

MBZ: mebendazole; Kd: dissociation constant; IC50: inhibitory concentration 50%; DYRK1B: dual specificity tyrosine-phosphorylation-regulated kinase 1B; LPS: lipopolysaccharide; IFNγ: interferon gamma; PBMC: peripheral blood mononuclear cells; IL13: interleukin-13; PMA: phorbol-12-myristate-13-acetate; IL4: interleukin-4; DMSO: dimethylsulfoxide; ABL: Bcr-Abl tyrosine-kinase; BRAF: serine/threonine-protein kinase B-Raf; ROS: reactive oxygen species; IL1β: interleukin-1 beta; TNF: tumor necrosis factor; VEGF: vascular endothelial
growth factor, DC: dendritic cell, IL-18: interleukin-18, ERK: extracellular signal-regulated kinase, CAR T: chimeric antigen receptor T cells.

Authors’ contributions
Experimental design: RL, KB, PN, MF, AL, VP, CA. Experimental work: KB, MB, ML, JR. Data analysis: KB, MB, RL. Writing manuscript: RL, PN, AL, MF. Reviewing manuscript: All authors. All authors read and approved the final manuscript.

Author details
1 Department of Medical Sciences, Division of Cancer Pharmacology and Computational Medicine, Uppsala University, 75185 Uppsala, Sweden. 2 Department of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden.

Acknowledgements
We thank In Vitro and Systems Pharmacology facility of the Science for Life Laboratory for helpful assistance. The study was supported by the Swedish Cancer Society and the Lions Cancer Research Fund.

Competing interests
RL, PN and MF are co-founders and shareholders of Repos Pharma AB, a small Swedish research and development company dedicated to investigations of drug repositioning in the cancer area. AL is chairman of the board. The present work was funded only by academic grants. The remaining authors declare no competing interests.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Funding
The study was supported by the Swedish Cancer Society, the Swedish Research Council (VR) and the Lions Cancer Research Fund. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 9 January 2019 Accepted: 15 April 2019 Published online: 22 April 2019

References
1. Pantokratora P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent. Eancermedicalscience. 2014;8:443.
2. Doudican N, Rodriguez A, Osman I, Orlow SJ. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res. 2008;6:1308–15.
3. Bai R-Y, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ. Antiparasitic meben-
dazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-oncology. 2011;13:974–82.
4. Sasaki J-I, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T. The antihelminthic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther. 2002;1:1201–9.
5. Martarelli D, Pompei P, Baldi C, Mazzoni G. Mebendazole inhibits growth of human adenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol. 2008;61:809–17.
6. Mukhopadhyay T, Sasaki J-I, Ramesh R, Roth JA. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2002;8:2963–9.
7. Nygren P, Fryknas M, Agerup B, Larsson R. Repositioning of the anthel-
mintic drug mebendazole for the treatment of colon cancer. J Cancer Res Clin Oncol. 2013;139:2133–40.
8. Doudican NA, Byron SA, Pollock PM, Orlow SJ. XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anticancer Drugs. 2013;24:181–8.
9. Bai R-Y, Staedtke V, Rudin CM, Buzn F, Riggins GJ. Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro Oncol. 2015;17:415:545–54.
10. Bodhiniyake J, Symons M, Boockvar JA. Repurposing mebendazole for the treatment of medulloblastoma. Neurosurgery. 2015;76:15:16–6.
11. Pinto LC, Soares BM, Pinheiro JD, Riggins GJ, Assumpção PR, Barbano RM, Montenegro RC. The antihelminthic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model. Toxicol In Vitro. 2015;29:2038–44.
12. Dobrosotskaya IV, Hammer GD, Schteingart DE, Matren KE, Worden FP. Mebendazole monotherapy and long-term disease control in meta-
static adenocortical carcinoma. Endocr Pract. 2011;17:659–69.
13. Larsson R, Nygren P. Drug repositioning from bench to bedside: tumour remission by the antihelminthic drug mebendazole in refractory meta-static colon cancer. Acta Oncol. 2013;52:1–2.
14. Larsen AR, Bai R-Y, Chung JH, Borodovsky A, Rudin CM, Riggins GJ, et al. Repurposing the antihelminthic mebendazole as a hedgehog inhibitor. Mol Cancer Ther. 2015;14:13–4.
15. Blom K, Senkowski W, Jarvis M, Berglund M, Rubin J, Lenhammar L, et al. The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLK-dependent inflammasome activation. Immunopharmacol Immunotoxicol. 2017;39:199–210.
16. Rubin J, Mansoori S, Blom K, Berglund M, Lenhammar L, Andersson C, et al. Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing. Oncotarget. 2018;9:30805–13.
17. Stewart DA, Yang Y, Makowski L, Troester MA. Basal-like breast cancer cells induce phenotypic and genomic changes in macrophages. Mol Cancer Res. 2012;10:727–38.
18. Davis MI, Hunt JP, Hergrass S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29:1046–51.
19. Issa NT, Peters OJ, Byers SW, Dakshamunurthi S. RepurposeVS: a drug repurposing-focused computational method for accurate drug-target signature predictions. Comb Chem High Throughput Screen. 2015;18:784–94.
20. Becker W. A wake-up call to quiescent cancer cells—potential use of DYRK1B inhibitors in cancer therapy. FEBS J. 2018;285:1203–11.
21. Hu J, Deng H, Friedman EA. Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition. Int J Cancer. 2013;132:2258–69.
22. Ewton DZ, Hu J, Vilenchik M, Deng X, Luk K-C, Polonskaia A, et al. Inacti-
vation of mYK/dYRK1B kinase targets quiescent pancreatic cancer cells. Mol Cancer Ther. 2011;10:2104–14.
23. Jin K, Ewton DZ, Park S, Hu J, Friedman E. Mirk regulates the exit of colon cancer cells from quiescence. J Biol Chem. 2009;284:22916–25.
24. Ashford AL, Oxley D, Kettle J, Hudson K, Guichard S, Cook SJ, et al. A novel DYRK1B inhibitor, AZ191, demonstrates that DYRK1B acts inde-
pendently of GSK3B to phosphorylate cyclin D1 at theroine-286, not theroine-288. Biochem J. 2013;457:43–56.
25. Lambrechts N, Verstraeten S, Lodewyckx H, Witters H, Nelissen I, Van Den Heuvel R, et al. THP-1 monocytes but not macrophages accom-
pany alternative for CD34+ dendritic cells to identify chemical skin sensitizers. Toxicol Appl Pharmacol. 2009;236:221–30.
26. Corti D, Galbiati V, Gatti N, Marininovich M, Galli CL, CORSINI E. Optimiza-
tion of the THP-1 activation assay to detect pharmaceuticals with potential to cause immune mediated drug reactions. Toxicol In Vitro. 2015;29:1339–49.
27. Galbiati V, Papale P, Kummer A, Corsini E. In vitro models to evaluate drug-induced hypersensitivity: potential test based on activation of dendritic cells. Front Pharmacol. 2016;7:204.
28. Miyazawa M, Ito Y, Yoshida Y, Sakaguchi H, Suzuki H. Phenotypic alterations and cytokine production in THP-1 cells in response to allergens. Toxicol In Vitro. 2007;21:428–37.

29. Chanput W, Mes JJ, Wichers HJ. THP-1 cell line: an in vitro cell model for immune modulation approach. Int Immunopharmacol. 2014;23:37–45.

30. Gao J, Zhao Y, Lu Y, Chen Y, Wei B, Tian J, et al. Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells. Cancer Cell Int. 2013;13:2.

31. Panni RZ, Linehan DC, DeNardo DG. Targeting tumor-infiltrating macrophages to combat cancer. Immunotherapy. 2013;5:1075–87.

32. Fridlender ZG. Modifying tumor-associated macrophages: an important adjunct to immunotherapy. Oncoimmunology. 2013;2:e26620.